EUVIMED · CrossrefJournal
Statistical Communications in Infectious Diseases
ISSN 1948-4690 · Walter de Gruyter GmbH
Latest articles
Tomorrow’s HIV Prevention Trials of Vaccines and Antibodies
HIV Sexual Networks: The Montreal Experience
Maximum a Posteriori Estimation in Dynamical Models of Primary HIV Infection
Episodic HIV Risk Behavior Can Greatly Amplify HIV Prevalence and the Fraction of Transmissions from Acute HIV Infection
Heterogeneity in Number and Type of Sexual Contacts in a Gay Urban Cohort
Is The Age-Period-Cohort Model Well Suited to an Epidemic Context? The Case of the French BSE Epidemic
Estimating Trends in Incidence, Time-to-Diagnosis and Undiagnosed Prevalence using a CD4-based Bayesian Back-calculation
Joint Spatio-Temporal Modeling of Mycobacterium bovis Infections in Badgers and Cattle – Results from the Irish Four Area Project
Publisher Notice
Publisher Notice
Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials
Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the ‘Mean Duration of Recent Infection’
Evaluating Anti-infective Drugs in the Resistant Pathogen Setting: Can We Use External Controls?
Publisher Notice
Spatially Informed Back-Calculation for Spatio-Temporal Infectious Disease Models
Analysis Populations in Anti-Infective Clinical Trials: Whom to Analyze?
Cross-Sectional HIV Incidence Estimation with Missing Biomarkers
Implementation of Power Law Network Models of Epidemic Surveillance Data for Better Evaluation of Outbreak Detection Alarms
Bayesian Design of Agricultural Disease Transmission Experiments for Individual Level Models
Designing & Conducting Trials to Reliably Evaluate HIV Prevention Interventions
Regulatory Perspectives for Streamlining HIV Prevention Trials
Ongoing Vaccine and Monoclonal Antibody HIV Prevention Efficacy Trials and Considerations for Sequel Efficacy Trial Designs
Designing the Next Generation of HIV Prevention Efficacy Trials: Synopsis of a 2018 Symposium
The Modern Randomized Clinical Trial: Is it Time to Sharpen a Blunt Instrument?
The Connection between the Averted Infections Ratio and the Rate Ratio in Active-control Trials of Pre-exposure Prophylaxis Agents
Current and Future Challenges in Trial Design for Pre-Exposure Prophylaxis in HIV Prevention
Crossover and Repeated Randomization in Event Driven Trials for HIV Prevention: Addressing the Impact of Heterogeneity in Risk in the Trial Design
Accounting for informative sampling in estimation of associations between sexually transmitted infections and hormonal contraceptive methods
Advancing Novel PrEP Products – Alternatives to Non-Inferiority
Contact network uncertainty in individual level models of infectious disease transmission
EUVIMED